Journal of Physiology 2015-03-01

Statin myalgia is not associated with reduced muscle strength, mass or protein turnover in older male volunteers, but is allied with a slowing of time to peak power output, insulin resistance and differential muscle mRNA expression.

Joanne E Mallinson, Kanagaraj Marimuthu, Andrew Murton, Anna Selby, Kenneth Smith, Dumitru Constantin-Teodosiu, Michael J Rennie, Paul L Greenhaff

Index: J. Physiol. 593(5) , 1239-57, (2015)

Full Text: HTML

Abstract

Statins are associated with muscle myalgia and myopathy, which probably reduce habitual physical activity. This is particularly relevant to older people who are less active, sarcopaenic and at increased risk of statin myalgia. We hypothesised that statin myalgia would be allied to impaired strength and work capacity in older people, and determined whether differences aligned with divergences in lean mass, protein turnover, insulin sensitivity and the molecular regulation of these processes. Knee extensor strength and work output during 30 maximal isokinetic contractions were assessed in healthy male volunteers, nine with no statin use (control 70.4 ± 0.7 years) and nine with statin myalgia (71.5 ± 0.9 years). Whole body and leg glucose disposal, muscle myofibrillar protein synthesis (MPS) and leg protein breakdown (LPB) were measured during fasting (≈5 mU l(-1) insulin) and fed (≈40 mU l(-1) insulin + hyperaminoacidaemia) euglyceamic clamps. Muscle biopsies were taken before and after each clamp. Lean mass, MPS, LPB and strength were not different but work output during the initial three isokinetic contractions was 19% lower (P < 0.05) in statin myalgic subjects due to a delay in time to reach peak power output. Statin myalgic subjects had reduced whole body (P = 0.05) and leg (P < 0.01) glucose disposal, greater abdominal adiposity (P < 0.05) and differential expression of 33 muscle mRNAs (5% false discovery rate (FDR)), six of which, linked to mitochondrial dysfunction and apoptosis, increased at 1% FDR. Statin myalgia was associated with impaired muscle function, increased abdominal adiposity, whole body and leg insulin resistance, and evidence of mitochondrial dysfunction and apoptosis.© 2014 The Authors. The Journal of Physiology © 2014 The Physiological Society.

Related Compounds

Structure Name/CAS No. Articles
sodium chloride Structure sodium chloride
CAS:7647-14-5
sodium dodecyl sulfate Structure sodium dodecyl sulfate
CAS:151-21-3
L-leucine Structure L-leucine
CAS:61-90-5
SODIUM CHLORIDE-35 CL Structure SODIUM CHLORIDE-35 CL
CAS:20510-55-8
DL-Phenylalanine Structure DL-Phenylalanine
CAS:150-30-1
Octreotide acetate Structure Octreotide acetate
CAS:83150-76-9
2-Amino-4-methylpentanoic acid Structure 2-Amino-4-methylpentanoic acid
CAS:328-39-2
Creatine Structure Creatine
CAS:57-00-1